"Using MS Word documents for visit reporting wasted our CRAs’ time and the reviewer’s time. With Medidata’s cloud-based CTMS, which structures visit report data, CRAs spend 40 percent less time completing a report and site correspondences. We’ve also noticed a reduction in review-to-approval cycle times from 16 days to seven …

“Medidata is a valued and trusted partner. We use a range of their solutions which have allowed us to manage various unique and complex study requirements without having to use custom programming. This has ensured consistent and efficient trial execution.”

"When compared with traditional cardiovascular trials that engage hundreds or thousands of sites, this technology allowed us to enroll 15,000 participants from 40 centers. We think this infrastructure and approach will facilitate studies that can be direct-to-patient, easier for patients and investigators, and faster to completion."

"We didn’t go shopping, we knew we wanted to use Medidata and it was a matter of working to find the right study build model to fit our business needs.”

"The Medidata products are very innovative and support our very complex oncology studies."

"Our partnership with Medidata has been very collaborative from a data management perspective in rolling out all the new applications and tools and integrating them with EDC. It’s made data management easier for reviewing the data, drawing out metrics, and building the forms. It’s an easier platform to design and …

"We needed to find a trusted partner to work with us, to grow with us AND deliver and provide innovative technology solutions for our clinical trials, we found that partner in Medidata."

“Medidata AI literally rolled up their sleeves, helped us analyze the data, and suggested ways to improve our clinical trial design. They were essentially part of our statistical group. We worked with Medidata and leveraged that information when we went to the FDA.”

“The partnership with Medidata further underscores TissueTech’s commitment to evidence-based medicine, scientific integrity and continuous research and innovation. Medidata’s unified platform provides us with the technology foundation to scale our clinical research, address the complexity of today’s clinical trials, and build and maintain efficiencies as we continue to grow.”

“One of the things that attracted me to Medidata was their ability to have a support mechanism [beyond] internal experts. Having a broad reach across the globe and supporting end users with devices are important. These factors attracted me to the Medidata DCT Program because not all competitors have that …

“It is to everyone’s advantage to [use Medidata’s] unified platform so that there is one login. There is one way that people are accessing all the things they need to do with their data. If we’re thinking of patients and sites first, we have to think about that value…[so] they’re …

“Our partnership with Medidata has enabled us to offer top-notch service to sponsors. In the last decade, we’ve embraced the latest Rave EDC technology, including eCOA/ePRO via the Patient Cloud and Rave Coder. We’ve successfully configured intricate study designs, from early-phase oncology with numerous protocol changes to rare disease studies …

“By using a system - that both the pharmaceutical industry recognizes, and the regulators accept - to execute high quality clinical trials, our mission to bring better treatments to patients faster can, ultimately, be realized.”

“Having our documentation in a secure, validated environment enables an ease of use for authoring, review, and approval. This allows us to pay attention to other things so we can focus on our product development.”

"Edge Payments stood out as a true end-to-end solution, and for its ability to reimburse sites quickly and accurately by directly integrating with Rave EDC– important as we invest in processes and technology that help us continue to stand out as a top-ranked performer for service and customer loyalty.”